RE: Anybody15 May 2025 08:20
And a very important product this will prove to be to the financial gain of both investor & company alike.
For those ppl that have missed ALL the previous important posts re P140 AKA Lupuzor here it is again.
P140, also known as Lupuzorโข, is a peptide-based drug developed by ImmuPharma PLC for the treatment of systemic lupus erythematosus (SLE). It has a unique mechanism of action that is non-immunosuppressive, meaning it does not block the body's ability to mount an immune response.
Recently, ImmuPharma announced a Phase 2/3 adaptive clinical trial for P140, following guidance from the FDA. This trial will involve higher concentrations of subcutaneous dosing and revised patient inclusion criteria. The company is optimistic about its potential as a safe and effective therapy for lupus patients.
I am sure that the patients will have Tigers patience - :) and await further news - Nudge nudge don't hold a grudge :)
Always happy to help OSD.